On 7 August 2009 Novo Nordisk initiated its share repurchaseprogramme in accordance with the provisions of the EuropeanCommission's regulation no 2273/2003 of 22 December 2003, alsoreferred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for anamount up to DKK 2.4 billion in the period from 10 August 2009 to18December 2009.

Since the announcement as of 31 August 2009, the followingtransactions have been made under the programme:

Number of Average Transaction shares purchase price value, DKKAccumulated, lastannouncement 1,125,000 353,840,25031 August 2009 75,000 317.7100 23,828,2501 September 2009 75,000 317.5400 23,815,5002 September 2009 80,000 317.3499 25,387,9923 September 2009 100,000 313.9550 31,395,5004 September 2009 66,000 316.1590 20,866,494Accumulated under theprogramme 1,521,000 479,133,986

With the transactions stated above, Novo Nordisk owns a total of26,357,808 treasury shares, corresponding to 4.3% of the sharecapital. The total amount of shares in the company is 620,000,000including treasury shares.Novo Nordisk is a healthcare company and a world leader indiabetescare. In addition, Novo Nordisk has a leading position withinareassuch as haemostasis management, growth hormone therapy and hormonereplacement therapy. Novo Nordisk manufactures and marketspharmaceutical products and services that make a significantdifference to patients, the medical profession and society. Withheadquarters in Denmark, Novo Nordisk employs more than 27,900employees in 81 countries, and markets its products in 179countries.Novo Nordisk's B shares are listed on the stock exchanges inCopenhagen and London. Its ADRs are listed on the New York StockExchange under the symbol 'NVO'. For more information, visitnovonordisk.com.

Company Announcement no 53 / 2009

This announcement was originally distributed by Hugin. The issuerissolely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.